Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
421.60
-7.58 (-1.77%)
At close: Oct 29, 2025, 4:00 PM EDT
421.60
0.00 (0.00%)
After-hours: Oct 29, 2025, 5:20 PM EDT
Madrigal Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts that cover Madrigal Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $521.09, which forecasts a 23.60% increase in the stock price over the next year. The lowest target is $405 and the highest is $590.
Price Target: $521.09 (+23.60%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Madrigal Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 5 | 6 | 7 | 8 |
| Buy | 4 | 4 | 4 | 2 | 2 | 3 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 10 | 10 | 10 | 9 | 10 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Piper Sandler | Piper Sandler | Buy Maintains $400 → $540 | Buy | Maintains | $400 → $540 | +28.08% | Oct 15, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $580 | Strong Buy | Initiates | $580 | +37.57% | Oct 15, 2025 |
| Oppenheimer | Oppenheimer | Buy Maintains $500 → $590 | Buy | Maintains | $500 → $590 | +39.94% | Oct 10, 2025 |
| B. Riley Securities | B. Riley Securities | Strong Buy Maintains $460 → $560 | Strong Buy | Maintains | $460 → $560 | +32.83% | Sep 29, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $428 → $526 | Strong Buy | Maintains | $428 → $526 | +24.76% | Sep 12, 2025 |
Financial Forecast
Revenue This Year
890.55M
from 180.13M
Increased by 394.38%
Revenue Next Year
1.47B
from 890.55M
Increased by 64.73%
EPS This Year
-9.97
from -21.90
EPS Next Year
4.42
from -9.97
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 953.3M | 1.9B | |||
| Avg | 890.6M | 1.5B | |||
| Low | 816.8M | 1.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 429.2% | 109.9% | |||
| Avg | 394.4% | 64.7% | |||
| Low | 353.4% | 23.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -5.62 | 25.67 | |||
| Avg | -9.97 | 4.42 | |||
| Low | -14.95 | -6.76 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | |||
| Avg | - | - | |||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.